Literature DB >> 22863066

Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis.

Carla Ferrándiz-Pulido1, Emili Masferrer, Ines de Torres, Belen Lloveras, Javier Hernandez-Losa, Sergio Mojal, Carlos Salvador, Juan Morote, Santiago Ramon y Cajal, Ramon M Pujol, Vicente Garcia-Patos, Agustin Toll.   

Abstract

BACKGROUND: Penile squamous cell carcinoma (PSCC) is a tumor with a high metastatic potential. In PSCC the attributable fraction to human papillomavirus (HPV) is not well established.
OBJECTIVE: We sought to provide novel data about the prevalence of HPV in a large series of penile intraepithelial neoplasia (PeIN) and invasive PSCC, correlating the results with the histologic subtype, p16(INK4a) immunostaining, and prognosis.
METHODS: A total of 82 PSCC were included in the study, 69 invasive and 13 PeIN. HPV detection was performed by polymerase chain reaction with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridization line probe assay. P16(INK4a) immunohistochemical expression on tissue microarrays was also analyzed.
RESULTS: HPV DNA was identified in 31 of 77 (40.2%) PSCC (22 of 67 invasive and 9 of 10 PeIN). In 25 of 31 (80.6%) cases HPV-16 was identified. HPV detection was significantly associated with some histologic subtypes: most basaloid and warty tumors were high-risk HPV (hrHPV) positive, whereas only 15% of usual PSCC were hr-HPV positive. All hrHPV-positive PSCC had an adjacent undifferentiated PeIN. Strong p16(INK4a) immunostaining correlated with hrHPV infection. Most undifferentiated PeIN showed p16(INK4a) immunohistochemical overexpression. Both hrHPV-positive and p16(INK4a)-positive tumors showed a better overall survival without reaching statistical significance. LIMITATIONS: This was a retrospective study.
CONCLUSIONS: Our results suggest that most hrHPV-positive PSCC develop from undifferentiated hrHPV-positive PeIN. P16(INK4a) immunostaining may be useful in identifying both etiologically related hrHPV-positive tumors and those with better outcome. The routine use of p16(INK4a) staining should be incorporated in histologic evaluation of PSCC.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863066     DOI: 10.1016/j.jaad.2012.05.029

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

1.  Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor.

Authors:  Hellen Kuasne; Mateus C Barros-Filho; Fábio A Marchi; Sandra A Drigo; Cristovam Scapulatempo-Neto; Eliney F Faria; Silvia R Rogatto
Journal:  Virchows Arch       Date:  2018-08-11       Impact factor: 4.064

2.  Prevalence of human papillomavirus and implication on survival in Chinese penile cancer.

Authors:  Chengbiao Chu; Keming Chen; Xingliang Tan; Jiangli Lu; Yuanzhong Yang; YiJun Zhang; Kai Yao; Yun Cao
Journal:  Virchows Arch       Date:  2020-05-19       Impact factor: 4.064

3.  Human papilloma virus status of penile squamous cell carcinoma is associated with differences in tumour-infiltrating T lymphocytes.

Authors:  Philipp Lohneis; Sengül Boral; Andreas M Kaufmann; Annika Lehmann; Christiane Schewe; Manfred Dietel; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Virchows Arch       Date:  2014-12-28       Impact factor: 4.064

Review 4.  [Conventional grading vs. molecular grading : Decision aids for clinical routine].

Authors:  C Kakies; D Louise Dräger; P Spiess; O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2021-06-28       Impact factor: 0.639

5.  Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort.

Authors:  Kamran Zargar-Shoshtari; Philippe E Spiess; Anders E Berglund; Pranav Sharma; Julio M Powsang; Anna Giuliano; Anthony M Magliocco; Jasreman Dhillon
Journal:  Clin Genitourin Cancer       Date:  2015-12-23       Impact factor: 2.872

Review 6.  [Molecular characterization of penile cancer : Literature review of new prognostic markers and potential therapeutic targets].

Authors:  M May; S D Brookman-May; T H Ecke; M Burger
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

7.  The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.

Authors:  Julie Steinestel; Andreas Al Ghazal; Annette Arndt; Thomas J Schnoeller; Andres J Schrader; Peter Moeller; Konrad Steinestel
Journal:  BMC Cancer       Date:  2015-04-03       Impact factor: 4.430

8.  P16INK4a expression in patients with penile cancer.

Authors:  Vicenilma de Andrade Martins; Jaqueline Diniz Pinho; Antonio Augusto Lima Teixeira Júnior; Leudivan Ribeiro Nogueira; Fábio França Silva; Victor Eduardo Maulen; André Salim Khayat; José de Ribamar Rodrigues Calixto; Herikson Araújo Costa; Leandra Naira Zambelli Ramalho; Gyl Eanes Barros Silva
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

9.  Overexpression of ANXA1 in penile carcinomas positive for high-risk HPVs.

Authors:  Marilia Freitas Calmon; Mânlio Tasso de Oliveira Mota; Érica Babeto; Natália Maria Candido; Ana Paula Girol; Carlos Fabian Mendiburu; Jane Lopes Bonilha; Rodrigo Vellasco Duarte Silvestre; Bruno Miziara Rosa; Jorge Alberto Thomé; Gustavo Hernandez Américo Medeiros; Fernando Augusto Soares; Gustavo Cardoso Guimarães; José Germano Ferraz de Arruda; Sonia Maria Oliani; Luisa Lina Villa; José Vassallo; Paula Rahal
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Prognostic Significance of P16INK4a Expression in Penile Squamous Cell Carcinoma: A Meta-Analysis with Trial Sequential Analysis.

Authors:  Jiayi Zhang; Hengcheng Zhang; Yanyan Xiu; Hong Cheng; Min Gu; Ninghong Song
Journal:  Biomed Res Int       Date:  2018-07-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.